Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07566988 · ClinicalTrials.gov registry record
A Real-world Study Comparing the Effectiveness of Ofatumumab and Ocrelizumab Treatment in Multiple Sclerosis Patients
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 2,604
- Enrollment target
NCT07566988: Completed study, sponsored by Novartis Pharmaceuticals.
NCT07566988 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 2,604 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07566988 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 2,604 participants
- Enrollment target
Study Summary
The aim of this study was to compare the effectiveness and economic burden of ofatumumab (OMB) and ocrelizumab (OCR) treatment in multiple sclerosis (MS) patients in the United States using data from an administrative claims database.
Primary Outcome
ARR was defined as the number of relapse episodes per patient-year (PPY) during the follow-up period.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,604 participants |
| Start Date | 2024-10-25 |
| Est. Completion | 2025-04-30 |
What the finished NCT07566988 record still lists
NCT07566988 is an observational study that tracks outcomes without assigning an intervention. Its 2,604 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT07566988 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07566988 about?
NCT07566988 is a clinical study titled "A Real-world Study Comparing the Effectiveness of Ofatumumab and Ocrelizumab Treatment in Multiple Sclerosis Patients". The aim of this study was to compare the effectiveness and economic burden of ofatumumab (OMB) and ocrelizumab (OCR) treatment in multiple sclerosis (MS) patients in the United States using data from an administrative claims database.
What is the current status of trial NCT07566988?
This trial is currently completed. The enrollment target is 2,604 participants. The study started on 2024-10-25. Estimated completion is 2025-04-30.
Who is sponsoring clinical trial NCT07566988?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06033950 · 2,600 participants · Phase 3
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
- NCT06574672 · 2,600 participants · NA
Embedded Palliative Care in the MICU
- NCT06370520 · 2,592 participants
Screening Emotions in Adolescents at the Hospital for mTBI
- NCT06455085 · 2,634 participants · NA
RESTORE: REducing Future fractureS and Improving ouTcOmes of fRagility fracturE
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI